News | July 13, 2008

Micrus Endovascular Receives FDA Approval for Intracranial Stent Clinical Trial

July 14, 2008 - Micrus Endovascular Corp. today said the Pharos Vitesse Intracranial Stent Study for Ischemic Therapy (VISSIT) clinical trial application has been conditionally approved by the FDA.

The Pharos Vitesse intracranial stent is Micrus Endovascular’s second balloon-expandable stent for the treatment of intracranial ischemic stenosis and is the subject of an investigational device exemption (IDE) study designed to compare the clinical outcomes between patients treated with the stent and another medical therapy. The company is in the process of initiating study sites in the U.S., Europe and China.

The company said its new stent is designed with advances for improved handling and navigability and incorporates a proprietary coating that we believe may reduce the need for retreatment due to restenosis.

The Pharos Vitesse is manufactured exclusively for Micrus Endovascular through a collaborative agreement with Switzerland-based Biotronik AG. It enables the intracranial delivery and deployment of a stent in one step, eliminating the need for pre-dilation of constricted vasculature.

For more information: www.micruscorp.com


Additional Content

News | Cardiovascular Surgery

May 4, 2026 — Johnson & Johnson recently announced new data from a novel U.S. pilot single-arm trial that evaluated the ...

Home May 05, 2026
Home
News | Cardiovascular Surgery

March 24, 2026 — iPerf, a company specializing in the development of medical devices for cardiopulmonary support, has ...

Home March 25, 2026
Home
News | Cardiovascular Surgery

Feb. 11, 2026 —The American Roentgen Ray Society (ARRS) has announced the following radiologists, as well as their ...

Home February 13, 2026
Home
News | Cardiovascular Surgery

Feb. 11, 2026 – Columbia HeartSource, an extension of Columbia University Irving Medical Center’s Department of Surgery ...

Home February 12, 2026
Home
News | Cardiovascular Surgery

Feb. 6, 2026 — Robert Wood Johnson University Hospital (RWJUH), in partnership with Rutgers Robert Wood Johnson Medical ...

Home February 06, 2026
Home
Subscribe Now